<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698503</url>
  </required_header>
  <id_info>
    <org_study_id>12380-6</org_study_id>
    <nct_id>NCT00698503</nct_id>
  </id_info>
  <brief_title>A Clinical Investigation of the M2a- 38™ Hip System</brief_title>
  <official_title>M2a- 38™ Hip System Prospective Data Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomet Orthopedics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <brief_summary>
    <textblock>
      The purpose of this prospective clinical data collection is to document the performance and&#xD;
      clinical outcomes of the M2a- 38™ Hip System&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to low follow up&#xD;
  </why_stopped>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>12 weeks, 1 year, 3 years, 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of revisions and removals</measure>
    <time_frame>Any time</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">190</enrollment>
  <condition>Non-inflammatory Degenerative Joint Disease</condition>
  <condition>Osteoarthritis</condition>
  <condition>Avascular Necrosis</condition>
  <arm_group>
    <arm_group_label>M2a- 38™ Hip System</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have already made the decision to undergo Total Hip Replacement and will&#xD;
        receive the M2a- 38™ Hip System&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients having primary cemented or cementless total hip replacement for&#xD;
             non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnosis&#xD;
             of osteoarthritis, avascular necrosis, traumatic arthritis, subcapital fracture, legg&#xD;
             perthes, slipped capital epiphysis, fracture of the pelvis, diastrophic variant.&#xD;
&#xD;
          -  Patients with full skeletal maturity&#xD;
&#xD;
          -  Patients undergoing unilateral total hip arthroplasty or bilateral total hip&#xD;
             arthroplasty, either staged or simultaneously&#xD;
&#xD;
          -  Patients of all races and gender&#xD;
&#xD;
          -  Patients who are able to follow postoperative care instructions&#xD;
&#xD;
          -  Patients who are able and willing to return for follow-up evaluations&#xD;
&#xD;
          -  Patients have preoperative total Harris Hip Score less than 70 with at least moderate&#xD;
             pain.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with inflammatory degenerative arthritis (IDJD) to include the&#xD;
             following composite diagnoses: rheumatoid arthritis, systemic lupus erythematous,&#xD;
             pigmented villonodular synovitis, juvenile rheumatoid arthritis and other arthritic&#xD;
             processes of inflammatory or autoimmune etiology.&#xD;
&#xD;
          -  Patients less than 18 years.&#xD;
&#xD;
          -  Patients with the presence of a previous prosthetic hip replacement device (any type,&#xD;
             including surface replacement arthroplasty, endoprosthesis, etc.)in the hip joint to&#xD;
             be operated.&#xD;
&#xD;
          -  Patients with previous Girdlestone procedures.&#xD;
&#xD;
          -  Patients with above the knee amputation of the contralateral and/or ipsilateral leg.&#xD;
&#xD;
          -  Patients with osteoporosis, or marked bone loss which would preclude proper fixation&#xD;
             of the prosthesis.&#xD;
&#xD;
          -  Patients who are pregnant.&#xD;
&#xD;
          -  Patients with an active or suspected infection in or around the hip.&#xD;
&#xD;
          -  Patients with Parkinson's disease.&#xD;
&#xD;
          -  Patients with vascular insufficiency, muscular atrophy, or neuromuscular disease in&#xD;
             the affected limb.&#xD;
&#xD;
          -  Patients with severe instability or deformity of the ligaments and/or surrounding soft&#xD;
             tissue which would preclude stability of the prosthesis.&#xD;
&#xD;
          -  Patients with a highly communicable disease or diseases that may limit follow-up (e.g.&#xD;
             immuno-compromised conditions, hepatitis, active tuberculosis, neoplastic disease,&#xD;
             etc.).&#xD;
&#xD;
          -  Patients unwilling or unable to comply with a rehabilitation program for a cemented or&#xD;
             cementless total hip replacement or who indicate difficulty or inability to return for&#xD;
             follow-up visits prescribed by the study protocol.&#xD;
&#xD;
          -  Patients with previous hip surgery or conditions that may interfere with the total hip&#xD;
             replacement's survival or outcome, e.g., Paget's disease, Charcot's disease, severe&#xD;
             osteoporosis compromising bone stock (Dorr type C bone).&#xD;
&#xD;
          -  Patients who qualify for inclusion in the study, but refuse consent to participate in&#xD;
             the study.&#xD;
&#xD;
          -  Patients with a &quot;fused&quot; hip.&#xD;
&#xD;
          -  Patients who have had a total hip arthroplasty on the contralateral hip within the&#xD;
             last year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth J Beres, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director, Clinical Research, Biomet Orthopedics, LLC</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metal on Metal</keyword>
  <keyword>Total Hip Arthroplasty</keyword>
  <keyword>Total Hip Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

